Longeveron Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.3M
- Price
- $2.38
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.25%
- Volume
- 36.7K
About
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Quick stats
Shares outstanding3.0M
Computed float—
Float / sharesUnknown
Cash runway (months)2.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001721484
Websitehttps://www.longeveron.com
AI Summary
AI-generated1/21
minorneutralother
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron will participate in three longevity/aging investment conferences in October 2026: the ARDD meeting in Boston, the Abundance Longevity Trip (virtual), and the Longevity Partnering Forum in South San Francisco.
The release recaps that laromestrocel Phase 2b frailty data was published in Cell Stem Cell and that the company won a $1 million XPRIZE Healthspan Milestone 2 Award, with a shot at a grand prize of up to $81 million.
It also highlights a new medRxiv preprint of post-hoc Phase 2a CLEAR MIND (n=49) analysis suggesting laromestrocel may reduce neuroinflammation in Alzheimer's disease; the data is not peer-reviewed and the product remains investigational.
Red flags
- Alzheimer's analysis is an unreviewed preprint with post-hoc exploratory design
- Forward-looking statements reference going-concern, cash conservation, and continued Nasdaq listing risks